Physician profile
Harrison Daniel
NPI 1437680154
$7,741.58
in general payments reported to CMS, 2019-2025
25 companies · $3,490 in 2025
The $3,490 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.72 · 2021: $386 · 2022: $518 · 2023: $1,315 · 2024: $2,018 · 2025: $3,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,782 · Education: $41.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,782.11 |
| Education | $41.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,868.80 | 2020-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,342.59 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $819.47 | 2024-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $785.31 | 2024-2025 | Voquezna |
| Genzyme Corporation | $478.75 | 2023-2025 | |
| Ardelyx, INC. | $344.71 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $328.72 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $260.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $221.76 | 2023-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $191.06 | 2023-2025 | Dupixent |
| Celgene Corporation | $162.56 | 2023-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $121.83 | 2022 | |
| Lilly USA, LLC | $112.99 | 2024-2025 | Omvoh |
| Boston Scientific Corporation | $108.65 | 2021-2023 | Captivator II, Wallflex Duodenal |
| Intercept Pharmaceuticals, INC. | $108.14 | 2023-2025 | Ocaliva |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $90.99 | 2024-2025 | |
| Novo Nordisk INC | $76.70 | 2023-2024 | Ozempic, Rybelsus |
| Ipsen Biopharmaceuticals, INC | $70.04 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $57.35 | 2023-2024 | Dificid |
| Celltrion USA INC. | $55.18 | 2024-2025 | Zymfentra, Vegzelma |
| Pfizer INC. | $53.45 | 2024-2025 | |
| Albireo Pharma, INC. | $39.37 | 2024 | Bylvay, Iqirvo |
| Sandoz INC. | $17.88 | 2023 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.04 | 2023 | Cyltezo |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harrison Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.